Nodular lymphocyte predominant Hodgkin lymphoma
ICD-10 C81.0 is a billable code used to indicate a diagnosis of nodular lymphocyte predominant hodgkin lymphoma.
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma characterized by the presence of large, atypical Reed-Sternberg cells surrounded by a background of small lymphocytes. This lymphoma typically presents in younger adults and is often localized to lymph nodes, particularly in the cervical region. Patients may exhibit B-symptoms such as fever, night sweats, and weight loss, although these symptoms are less common in NLPHL compared to classical Hodgkin lymphoma. The disease is generally indolent, with a favorable prognosis, especially when diagnosed at an early stage. Staging is crucial and follows the Ann Arbor classification, which assesses the extent of lymph node involvement and any extranodal disease. Treatment protocols often include a combination of chemotherapy and radiation therapy, tailored to the stage of the disease and the patient's overall health. The unique histological features of NLPHL necessitate careful differentiation from other lymphomas, making accurate coding essential for appropriate management and reimbursement.
Detailed pathology reports, staging information, and treatment plans.
Diagnosis confirmation, treatment planning, and follow-up care.
Ensure accurate histological classification and staging documentation.
Imaging reports that detail lymph node involvement and any extranodal disease.
Imaging for staging and treatment response assessment.
Clear documentation of imaging findings related to lymphatic structures.
Used for patients receiving chemotherapy for NLPHL.
Document the specific chemotherapy agents used and the duration of treatment.
Oncology specialists should ensure accurate coding of chemotherapy regimens.
Patients with NLPHL generally have a favorable prognosis, especially when diagnosed at an early stage. The 5-year survival rate is high, and many patients can achieve long-term remission.
